Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

HORSHOLM, Denmark, July 14 /PRNewswire/ -- The Board of Directors of Santaris Pharma has approved the Interim Report for the period 1 January to 30 June 2009.

    - The loss after tax realised in the 2nd quarter of 2009 was
      21,6m DKK (2,9m EUR) compared to 29,8m DKK (4,0m EUR) in the 2nd
      quarter of 2008.

    - As at June 30, 2009 the capital resources totalled 175,4m
      DKK (23,6m EUR).

    - In Q2 the SPC3649 compound targeting hepatitis C finalized a
      single dose First/In/Man study with encouraging results and a multiple
      ascending dose study in healthy volunteers is scheduled to commence in
      Q3 2009.

    - Santaris Pharma's new lead candidate SPC4955 targeting
      apoliproteinB, the major cholesterol carrying protein in the blood, has
      been selected for preclinical trials.

    - Lead candidates targeting PCSK9, which is known to play a
      critical role in regulating cholesterol levels, have been selected for
      pharmacological studies.

    - The Collaboration with the Company's 3rd partner, Wyeth, was
      initiated during the first months of 2009 and is progressing according
      to the plan.

    (Logo: )

During the first half of 2009 Santaris Pharma continued to make satisfactory progress in its research and development programs within miRNA, metabolic disorders and infectious diseases. Key milestones achieved and other events during the quarter are summarized below.



SPC3649 is a potent and specific inhibitor of microRNA-122 known to be involved in cholesterol metabolism and in hepatitis virus replication in the liver. In April 2009, Santaris Pharma completed a Phase I First-in-Man single dose study of SPC3649 with 60 healthy volunteers and t

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
(Date:6/1/2015)... HEAD, N.J. , June 1, 2015  The ... launch a national innovative science curriculum for high school ... at the 16 th annual LIFE Event (LPGA ... at Mountain Ridge Country Club in West ... of the LPGA,s biggest stars raised more than $500,000 ...
(Date:6/1/2015)... LANSING, Mich. , June 1, 2015  Neogen Corporation ... the assets of Sterling Test House, a leading commercial food ... and that the acquired laboratory will serve as a base ... . Sterling Test House was ... virtually all of the food safety and water quality testing ...
(Date:6/1/2015)... June 1, 2015   Epic Sciences, Inc. , ... and offerings to personalize and advance the treatment and ... the available credit under its existing credit facility with ... increases the available capacity of the facility from $5 ... by 27 months to April 1, 2019.  The availability ...
(Date:6/1/2015)... 2015 Research and Markets( ... "2015 Strategies in the US Point-of-Care/POC ... offering. This new 373-page report ... analysis of the POC clinical chemistry market, ... technological trends, competitive landscape, and emerging opportunities ...
Breaking Biology Technology:Val Skinner Foundation Announces Partnership With Discovery Education 2Neogen acquires India food safety company 2Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... July 30 /PRNewswire-Asia/ -- Eli Lilly & Company ... they have,reached an amicable resolution of all ongoing ... and sale of gemcitabine,hydrochloride around the world. , ... settlement, Lilly has granted ScinoPharm a royalty bearing,license ...
... TOKYO, July 30 With a ... Pharmaceutical Co. Ltd., a subsidiary of,the Zydus group, one of ... looking to give a big boost to its operations,in the ... market in Japan is estimated at $ 60 bn the ...
... viable solar power cellscheap, flexible and easy to makehas ... of recent work* at the National Institute of Standards ... of the complex organic films at the heart of ... molecules to capture sunlight and convert it into electricity, ...
Cached Biology Technology:Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation 2"Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan" - Dr. Kailash Sharma, President, Japan Operations, Zydus Cadila 2NIST scientists study how to stack the deck for organic solar power 2
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... Researchers presented Phase III efficacy data from the GeparQuinto ... in combination with chemotherapy for patients with early breast ... Cancer Symposium, held Dec. 8-12. "We had ... combination of chemotherapy, trastuzumab, with the new combination of ...
... the World Health Organization Collaborating Centre for Metabolic Bone Diseases ... a FRAX calculator for Singapore. The FRAX tool ... by the WHO to help evaluate patients at low, medium ... factors, with or without the use of bone mineral density ...
... in recent years to reduce carbon emissions by increasing efficiency ... carbon emissions in China have grown dramatically during that same ... questions about who is to blame when the coal China ... are produced to manufacture goods exported back to places with ...
Cached Biology News:Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer 2WHO Fracture Risk Assessment Tool (FRAX) newly released for Singapore 2
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... of the COP9 signalosome complex (CSN), a ... processes. The CSN complex is an essential ... by mediating the deneddylation of the cullin ... complex is also involved in phosphorylation of ...
... 96 well Magnetic-Ring Stand is designed for ... U-bottom microplates. The stand has a plastic ... microtiter plate footprint. The use of 96 ... and easy magnetic separation. With this magnetic ...
Biology Products: